Compare Brunswick Corporation (BC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Incyte Corporation — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 4.6× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.16% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BC | INCY | |
|---|---|---|
Market Cap | $5.28B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $129.93 |
52-Week Low | $58.75 | $81.61 |
Enterprise Value | $7.28B | $20.04B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.
The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
